Evaluating the Effectiveness of International Travel Controls to Identify Monkeypox 1

Virus Infected Travelers 2

3 Authors

- Keisuke Ejima^{1,2,*,†}, Yuqian Wang^{1,†}, Akira Endo^{3,4,5,†}, Hiroaki Murayama⁶, Yun Shan Goh⁷, Alex R. 4
- Cook^{2,3,18}, Yong Dam Jeong^{8,9}, Shingo Iwami^{8,10,11,12,13}, Hyeongki Park⁸, Borame Sue Lee Dickens³, Shihui 5
- Jin³, Jue Tao Lim¹, Conrad En Zuo Chan², Po Ying Chia^{1,2,15}, Barnaby E. Young^{1,2,14}, Yang Yang^{15,16}, 6
- Martin Chio^{17,18}, David Chien Lve^{1,2,14,19}, Marco Aielli^{20,†} 7

8 Affiliations

- 9 ¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
- ²National Centre for Infectious Diseases, Singapore, Singapore 10
- 11 ³Saw Swee Hock School of Public Health, National University of Singapore and National University Health
- 12 System, Singapore, Singapore
- ⁴School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan. 13
- 14 ⁵Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical
- Medicine, London, UK. 15
- ⁶School of Medicine, International University of Health and Welfare, Narita, Japan 16
- 17 ⁷A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research
- 18 (A*STAR), Singapore, Singapore.
- 19 ⁸interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science,
- 20 Nagoya University, Nagoya, Japan.
- ⁹Department of Mathematics, Pusan National University, Busan, South Korea. 21
- ¹⁰Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. 22
- ¹¹Institute for the Advanced Study of Human Biology (ASHBi), Kvoto University, Kvoto, Japan. 23
- 24 ¹²NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
- ¹³Science Groove Inc. Fukuoka, Japan Note: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

- ¹⁴Tan Tock Seng Hospital, Singapore, Singapore 26
- ¹⁵Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious 27
- 28 Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital
- 29 Affiliated to Southern University of Science and Technology, Shenzhen, China
- ¹⁶National Clinical Research Center for Infectious Disease, Shenzhen, China 30
- ¹⁷National Skin Centre Singapore, Singapore, Singapore 31
- ¹⁸Duke-NUS Medical School, Singapore, Singapore 32
- ¹⁹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 33
- ²⁰Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and 34
- 35 Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA.
- * Corresponding authors: keisuke.ejima@ntu.edu.sg 36
- 37 [†] These authors contributed equally to this work.
- Keywords: mpox, mathematical model, false negative, PCR testing, public health, quarantine, health 38
- screening 39

40 Abstract

41 Introduction:

In August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid spread of mpox in African and beyond. International travel controls (ITCs), such as health screening and viral testing, could help avoid/delay the global spread of the monkeypox virus (MPXV), fostering preparedness and response efforts. However, it is not clear whether the viral tests at immigration are sufficient to avoid importation of MPXV and which samples should be used on the viral tests.

47 Methods:

We conducted a simulation study using epidemiological and viral load data to assess the effectiveness of health screening and PCR testing at immigration. This provides estimates of the proportion of infected travelers identified with this policy. Viral dynamics models were used to estimate false-negative rates of PCR tests with different detection limits according to testing regimens at three different sites: oropharynx, saliva, and rectum. We also simulated the effects of these border control methods on the recommended duration of a monitoring period for travelers from mpox-affected regions, during which individuals would self-monitor for symptoms and practice cautionary behavior.

55 **Results:**

Our results show that the combination of health screening and PCR testing of saliva swabs under an endemic scenario identify only 74% of MPXV infected travelers. The use of rectal swabs combined with health screening allows the identification of a marginally larger share of infected travelers (79%) compared to saliva swabs. A similar identification rate could be achieved by using more sensitive PCR tests (detection limit [DL]: 10 copies/mL vs. 250 copies/mL used in our baseline analysis). We estimated that travelers from mpoxaffected areas should monitor themselves and practice precautionary behavior for 16 days.

62 **Conclusion:**

Health screening and PCR testing at immigration are likely to miss a significant proportion of MPXV-infected travelers, thus a lengthy quarantine period would be required to prevent onward local transmission. Careful consideration on other factors such as economic costs and likelihood of widespread local outbreak will need

- to be weighed against the adoption of these measures to prevent local mpox transmission given MPXV 66
- 67 transmissibility and severity.

Introduction 68

Monkeypox virus (MPXV), the causative agent of mpox, has caused sporadic infections in African 69 countries for over 50 years mainly due to zoonotic spillover¹. Two clades, I and II, have been observed in 70 Central and West Africa, respectively². Clade I is associated with more severe symptoms and higher 71 72 mortality rates². In 2022, human-to-human transmission, mainly during sexual intercourse, of clade IIb caused a global epidemic³. In September 2023, a different subtype of mpox (clade Ib) began to spread in the 73 74 Democratic Republic of Congo (DRC). Notably, unlike the clade IIb epidemic, which predominantly 75 impacted men who have sex with men (MSM) populations, clade Ib infection was reported in a substantial 76 number of children and commercial sex workers^{4,5}, raising significant public health concerns. In response, the World Health Organization (WHO) declared the mpox outbreak a public health emergency of 77 international concern⁶. Furthermore, importations of the same subtype were identified in non-African 78 79 countries, including Thailand, Sweden, India, Germany, the United Kingdom, the United States, Canada and Belgium. Moreover, secondary transmission was also found in the United Kingdom and Germany⁷, raising 80 concerns about its potential for further international spread. 81

Implementing effective international travel controls (ITCs) is instrumental to reduce the spread of 82 83 infections to other regions and is especially important when local transmission is not yet established. Common ITCs include health screenings, viral testing (e.g., PCR and antigen tests), case isolation, and quarantine and/or 84 active monitoring of suspected cases⁸. Although avoiding case importation entirely may not be feasible, 85 86 delaying the spread may gain time to prepare resources and plan strategies to mitigate the impact of potential epidemics. In particular, health screening and viral tests play a critical role in preventing the importation of 87 88 infected individuals. Health screening aims to detect infected individuals who are symptomatic, while viral 89 tests are used both to confirm infection in symptomatic individuals and identify pre-symptomatic and 90 asymptomatic infected individuals. Given the relatively long incubation period of mpox (approximately 8 days 91 both for the clade IIb strain responsible for the 2022 outbreak and for historical strains – clade Ia and IIa)⁹, the probability of individuals traveling while pre-symptomatic is non-negligible. 92

To delay (and/or potentially avoid) an epidemic being seeded by international travelers, health 93 screenings and viral tests are often paired with quarantine periods for travelers^{10,11}. Quarantine measures vary 94

widely depending on the pathogen's severity and transmissibility and the political milieu. The implementation 95 can range from quarantine in dedicated facilities, as seen in the early stages of the COVID-19 pandemic in 96 China and other countries with effective pandemic control, to self-quarantine at home¹², or simply monitoring 97 98 symptoms and practicing precautionary behavior¹³. Typically, the duration of quarantine is determined by the incubation period of the virus (e.g., the 95th/99th percentile). For instance, during the early phase of the 99 100 COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention (CDC) initially recommended a 14-day quarantine for individuals exposed to SARS-CoV- 2^{14} , based on epidemiological evidence suggesting 101 that the 99th percentile of the incubation period was 14 days¹⁵. However, for travelers from disease-prevalent 102 regions, such long quarantine periods may be overly conservative and suboptimal. For example, while the 103 mean incubation period of H1N1-2009 was 2.1 days¹⁶, the mean time from departure to symptom onset for 104 (infected) Japanese travelers returning from Hawaii was only 0.7 days¹⁷. 105

For mpox, several questions remain regarding international travel controls (ITCs) and quarantine measures. First, it is uncertain whether viral testing bundled together with health screening at immigration is sufficient to prevent the importation of MPXV. Second, with multiple sampling sites available, including saliva and rectum (details provided in the next section), it is unclear which sample type should be prioritized for viral testing. Third, if viral testing proves insufficient, the appropriate quarantine duration for travellers from mpox-affected countries who may have been exposed remains to be determined. To address these questions, we developed mathematical models informed by viral load data and epidemiological insights.

114 Methods

115 False negative rates from viral dynamics model

116 Critical to determining the effectiveness of border measures is the false negative rate of viral tests, 117 including PCR tests, which is influenced by the viral load and the ability of the test to detect the virus 118 (detection limit). Since the viral load varies throughout the course of an infection, increasing initially, 119 reaching a peak, and then declining, the false negative rate also changes over time¹⁵. In a previous study, we 120 estimated false negative rates for PCR tests for SARS-CoV-2 using a mathematical model of within-host 121 viral dynamics, considering the timing of tests and different detection limits¹⁸. Here we adapted the same 122 approach to estimate the false-negative rate of PCR tests for MPXV.

123

124 MPXV viral load data

To parameterize the viral dynamics model, we analyzed two prospective longitudinal cohort studies. 125 The first cohort enrolled 77 men with acute mpox infections (clade IIb) hospitalized in Shenzhen. China, 126 between June 9 and November 5, 2023¹⁹. Participants were followed up to 21 days after symptom onset. 127 Samples were collected every 2-3 days from various sites, including skin lesions, rectum, saliva, 128 oropharynx, urine, and plasma. The second cohort enrolled 25 individuals who had high-risk contact with 129 mpox infected patients in Antwerp, Belgium, between June 24 and July 31, 2022²⁰. Participants were 130 followed up for a maximum of 21 ± 2 days after inclusion, while infected participants were monitored until 131 they tested MPXV-PCR positive with typical mpox symptom onset and then referred to routine clinical care. 132 During weekly follow-up visits, blood, saliva, oropharyngeal swabs, genital swabs, anorectal swabs, and 133 skin lesion swabs were collected. Additionally, anorectal swabs, genital swabs, and saliva were also 134 collected through daily self-sampling. PCR sensitivity was higher with oropharynx, saliva, rectum, and skin 135 lesions (>70%), while PCR sensitivity was lower with urine, serum, genital swabs and plasma samples 136 (<50%). Hence, we have focused our analysis on samples with higher PCR sensitivity (oropharynx, saliva, 137 and rectum) for ITC purposes. It is worth noting that we have excluded the skin lesion data in the analysis, 138 as PCR testing on skin lesions can only be conducted after lesions are visible. Therefore, relying on skin 139 lesions for PCR testing at immigration to identify infected individuals is moot. Quantitative reverse 140

- 141 transcription PCR (qRT-PCR) was used to measure cycle threshold (Ct) values. To convert the Ct value to
- 142 viral load, we applied the following equation: $Ct = -3.611(log_{10}RNA) + 41.388$ as described in the
- 143 paper¹⁹. Ct values > 40 (i.e., $< 10^3$ copies/mL for viral load) are considered negative.
- 144

145 Viral dynamics model and fitting

To characterize the MPVX viral dynamics, we used the following system of ordinary differential equations, which accounts for the fundamental biological process of the infection within a host, including viral replication and elimination due to immune response:

149
$$\frac{dT(t)}{dt} = -\overbrace{\beta T(t)V(t)}^{\text{infection of uninfected cells}}$$

150
$$\frac{dI(t)}{dt} = \overbrace{\beta T(t)V(t)}^{\text{infection of uninfected cells}} - \overbrace{\delta I(t)}^{\text{removal of infected cells}}$$

151
$$\frac{dV(t)}{dt} = \overbrace{pI(t)}^{\text{production of viruses}} - \overbrace{cV(t)}^{\text{removal of viruses}}$$

where the variables T(t), I(t), and V(t) represent the number of uninfected target cells, number of infected 152 target cells, and amount of virus at t days after symptom onset, respectively. These represent the infection of 153 uninfected cells at rate $\beta T(t)V(t)$ and the removal of infected cells at rate $\delta I(t)$ cells per day, and the 154 production of virus at rate pI(t) and the removal of virus at rate cV(t) viral units per day. Note that we use 155 days after symptom onset as the time scale. The model parameters β , δ , p, and c represent the rate of virus 156 infection, death rate of infected cells, (per cell) viral production rate, and (per capita) clearance rate of the 157 virus, respectively. Under the quasi-steady-state assumption, the model is reduced to a two-dimensional 158 model as follows: 159

160
$$\frac{dg(t)}{dt} = -\beta g(t)V(t),$$

161
$$\frac{dV(t)}{dt} = \gamma g(t)V(t) - \delta V(t)$$

where g(t) is the fraction of uninfected target cell population at day t to that at day 0 (i.e., g(0) = 1), and V(t) is the amount of virus at day t (copies/mL), respectively. Note that time 0 corresponds to the day of

164 symptom onset. Details on the transformation of this model are reported in the reference²¹. The quasi-165 steady-state assumption is generally reasonable for most viruses causing acute infectious disease because the 166 clearance rate of virus (*c*) is typically much larger than the death rate of the infected cells (δ) as evidenced 167 by *in vivo* observations²¹⁻²³. Thus, we estimated the four parameters: β , γ , δ , and *V*(0) (viral load at the day 168 of symptom onset). We fit the viral dynamics model to the viral load data collected from the three different 169 sites (rectum, saliva, and oropharynx) independently using a non-linear mixed effect model.

The nonlinear mixed-effects model incorporates fixed effects and random effects accounting for 170 171 inter-site variability in viral dynamics. Specifically, the parameter for site k, $\theta_k (= \theta \times e^{\pi_k})$, is represented by the fixed effect, θ , and the random effect, π_k , is assumed to follow the Gaussian distribution with mean 0 172 and standard deviation Ω . The fixed effect (population parameter) and random effect were estimated by 173 using the stochastic approximation expectation-maximization (EM) algorithm and empirical Bayes' method, 174 175 respectively. We chose these methods because the EM algorithm is well-suited for estimating population-176 level parameters in the presence of latent variables, whereas the empirical Bayes allows us to efficiently estimate inter-site-level variations by using prior information. Using estimated parameters and a Markov 177 Chain Monte Carlo algorithm, we obtained the conditional distribution of model parameters for each site. 178 Left censoring was considered based on the lower limit of detection (Ct values < 40). Monolix 2023R1 179

180 (<u>https://www.lixoft.com</u>) was used for viral dynamics model fitting.

181

182 Simulation analysis to estimate false negative rates over time

183 We repeatedly randomly resampled a parameter set for individual *i* at site *k* (i.e., β_{ik} , γ_{ik} , δ_{ik} , and 184 $V(0)_{ik}$) from the estimated posterior distributions, and ran the viral dynamics model. The viral load obtained 185 by running the viral dynamics model is considered as the "*true*" viral load, $V_{ik}(t)$. However, PCR test 186 results are influenced by measurement error. To account for this, we added measurement error to the true

187 viral load to simulate *measured viral load*, $\hat{V}_{ik}(t)$, whereby $\log_{10} \hat{V}_{ik}(t) = \log_{10} V_{ik}(t) + \varepsilon_{ik}$,

188 $\varepsilon_{ik} \sim N(0, \sigma_k^2)^{24,25}$. As the time scale of the viral dynamics model is days after symptom onset, we corrected

189 the time scale to time after infection by adding incubation period, η , drawn from the incubation period

190 distribution obtained from the meta-analysis⁹. That says, $V_{ik}(\tau) = V_{ik}(t + \eta), \eta \sim \log N(1.92, 0.60)$

(mean=8.1, 95th percentile=18), where τ is the infection age (i.e., the time which has elapsed since 191 infection). The error distribution is obtained by fitting a normal distribution to the residuals (i.e., the 192 difference between the common logarithms of the true viral load and the measured viral load). We repeated 193 this process 10,000 times to create the viral-load distribution over time. The false-negative rate at site k at 194 infection age τ is computed as the proportion of cases with a viral load below the detection limit: $p_k(\tau) =$ 195 $\sum_{i=1}^{1000} I(\hat{V}_{ik}(\tau) < DL)/1000$, where DL is the detection limit, and I is the identity function. We used 250 196 copies/mL as the detection limit of PCR tests²⁶. As a sensitivity analysis, we performed the same simulation 197 using different detection limits, namely 10 and 1,000 copies/mL. 198

199

200 Detection rates by health screening and PCR tests and post-entry incubation periods for travelers

201 To assess the impact of health screenings and PCR tests, we examined a population of individuals infected during travel in mpox-affected countries and moving to non-mpox-affected countries. Upon arrival 202 in non-mpox-affected countries, the time elapsed since infection, referred to as the infection age (τ) , 203 represents the duration between the date of infection and the date of arrival at the travel destination. 204 Assuming that the mpox cases still were exponentially increasing at the country of origin at a growth rate r205 and travelers are exposed proportionally to the number of the cases, the number of infected (traveling) 206 individuals with infection age τ at immigration is described as follows: $i(\tau) = i_0 \exp(-r\tau)$, where i_0 is a 207 constant number representing those at infection age $\tau = 0$ ($j(0) = j_0$). Given that health screenings at 208 immigration detect individuals with symptoms, we aim to use PCR tests to identify asymptomatic 209 individuals at the time of entry. These individuals are modeled as being in the early stages of infection, 210 where the infection age τ is below the threshold for symptom manifestation. The probability of detecting an 211 asymptomatic individual with a PCR test is described as a function of viral load dynamics over τ , modeled 212 as $j_{pre}(\tau) = j_0 \exp(-r\tau)L(\tau)$, where $L(\tau)$ is the survival function of symptom development by infection 213 age τ . The survival function of symptom development $L(\tau)$ can be computed from the probability density 214 function of incubation period, $f(\tau)$, as $L(\tau) = 1 - \int_{0}^{\tau} f(u) du$. The number of pre-symptomatic individuals 215 who test negative for mpox on PCR tests conducted at immigration is represented by $j_{pre,neg}(\tau) =$ 216

217 $j_0 \exp(-r\tau)L(\tau)p(\tau)$, where $p(\tau)$ is the false-negative rate of PCR tests at infection age τ . The proportion

of infected travelers who develop symptoms and are subsequently identified by the health screenings at

immigration (including those who cancelled travel due to symptoms) can be modeled as H = 1 - 1

220 $\frac{\int_0^{\infty} j_{pre}(u)du}{\int_0^{\infty} j(u)du} = 1 - \frac{\int_0^{\infty} \exp\left(-ru\right)L(u)du}{\int_0^{\infty} \exp\left(-ru\right)du}.$ This assumes that the health screenings detect all symptomatic mpox

221 cases. The proportion of infected travelers identified through PCR testing can be modeled as T =

222
$$\frac{\int_0^\infty j_{pre}(u) - j_{pre,neg}(u)du}{\int_0^\infty j(u)du} = \frac{\int_0^\infty \exp(-ru)L(u)(1-p(u))du}{\int_0^\infty \exp(-ru)du}.$$
 Note that j_0 is cancelled in the derivation process of H

223 and T.

The quarantine period can be determined based on the incubation period, assuming that the time of 224 exposure is known – typically the 95th percentile of the incubation period distribution²⁷. However, in this 225 study, we assume that the timing of exposure is not known and only the timing of entrance to the country is 226 known. Therefore, the quarantine period begins upon entry into the country. To determine the appropriate 227 length, we estimated the remaining incubation period for pre-symptomatic individuals at immigration (time 228 from immigration to symptom onset, hereafter referred to as post-entry incubation period). The 95th, 80th, 229 and 70th percentiles of this post-entry incubation period were used to define the guarantine period. We 230 emphasize here that quarantine refers to self-monitoring for mpox symptoms and practicing precautionary 231 behavior (e.g., abstinence). 232

From the mathematical standpoint, we set the time after immigration, s, as a time scale. Given a maximum travel duration of k days, the number of individuals that developed symptoms at time s, i(s), can be modeled as

236
$$i(s) = \int_0^k f(s+u) \frac{j_{pre,neg}(u)}{L(u)} du = \int_0^k f(s+u) j_0 \exp(-ru) p(u) du$$

because those who are presymptomatic and test-negative on mpox PCR test at immigration with infection age u, $j_{pre,neg}(u)$, have already survived (i.e., did not develop symptoms) for u days at the time of immigration, L(u), and develop symptoms s days after immigration, when their infection age is s + u. In other words, the distribution of a presymptomatic and test-negative infected traveler's time from immigration to symptom onset, s, conditional to time from exposure to immigration being u and the absence

of symptoms by immigration is f(s + u)/L(u). As i(s) is a number, it can be normalized to be a probability density function of the post-entry incubation period as $i(s)/\int_0^\infty i(u)du$. Note that j_0 is cancelled after normalization. We also conducted sensitivity analyses under an epidemic scenario assuming $R_0 = 1.5$ ²⁸. **Supplemental Table 1** summarizes the variables used in this study. All epidemiological parameters except false-negative rate (obtained by fitting the viral dynamics model to the viral load data) are obtained from literature on clade IIb except incubation period (from clade Ia, IIa, and IIb) (**Supplemental Table 2**).

249

250 **Result**

251 Time-and-site-dependent false-negative rates

The viral load curve for each of the four sites shows a similar trend, but remarkable differences 252 (Figure 1). The peak viral load occurred at 5 days after symptom onset for rectum and oropharynx samples 253 and 6 days for saliva samples. Peak viral load levels from the rectum samples were the highest levels $(10^{6.8})$ 254 copies/mL), around ten-fold higher than from saliva samples $(10^{5.7} \text{ copies/mL})$, which in turn was around 255 ten-fold higher then from the oropharynx samples ($10^{4.8}$ copies/mL). MPXV remained detectable for varying 256 durations: 19 days for rectum, 18 days for saliva, and 14 days for oropharynx. We emphasize that the length 257 of viral shedding may exceed that of infectiousness, as the infectiousness threshold for mpox, 10^{6.5} 258 copies/mL²⁹, is higher than the detection limit. A comparison between the simulated viral load curves and 259 the observed data for each infected individual is shown in **Supplemental Figure 1**, showing good overall 260 concordance to the theoretical model. We also compared the estimated parameter values from the different 261 sites (Supplemental Figure 2) and found a moderate correlation in the viral dynamic parameters of 262 oropharynx and saliva. Estimated model parameters are reported in Supplemental Table 3. 263 The estimated viral dynamics allowed us to estimate false negative rate over time for various 264 detection limits: 10, 250, and 1000 copies/mL (Figure 2). Using 250 copies/mL as the reference detection 265 limit, we observed that the false negative rate is initially at 82%, 89%, 91% for rectum, saliva, and 266 267 oropharynx, respectively and then decreases towards the viral load peak and subsequently increases as the viral loads fall. The lowest false negative rates were 15%, 25%, and 34% for rectum, saliva, and oropharynx, 268

respectively, implying that even with the ideal timing, a high proportion of infections would be missed from border screening. The high false negative rate for oropharynx is explained by the relatively low mean viral load compared with saliva. Similar trends were observed for other detection limits, with higher detection limits generally associated with higher false negative rates.

Given the ease of saliva sampling, we selected saliva for PCR testing at immigration as a primary

analysis. Rectal and oropharyngeal swabs were considered for sensitivity analyses.

275

276 Effectiveness of health screenings and PCR tests in identifying infected travelers

Assuming an endemic situation at the source, health screenings at immigration will successfully

identify 62% of infected individuals (Figure 3). When PCR tests are conducted on saliva samples from all

279 pre-symptomatic individuals, an additional 12% of MPXV infected individuals will be identified (detection

280 limit: 250 copies/mL). Assuming a more sensitive detection limit of 10 copies/mL, the detection rate would

increase to 16%. A different fraction of MPXV infected travelers would be identified if rectal or

oropharyngeal swabs were to be collected: 17% and 11%, respectively, assuming a detection limit of 250

copies/mL. As the mean incubation period is 8.1 days and only those who are not symptomatic could be

identified by PCR tests at the border, the lower false-negative rate before the symptom onset yields to higher detection rate. Under the assumption of a growing epidemic (with R_0 of 1.5) at the source, health screenings at immigration would identify 51% of infected individuals (**Supplemental Figure 3**). 20, 14, and 12% more

cases would be identified by PCR tests on rectal, saliva, and oropharyngeal swabs, respectively.

288 Length of the quarantine period

We defined quarantine periods based on the 95th, 80th, and 70th percentiles of the incubation period and post-entry incubation period distribution, as illustrated in **Figure 4**. The 95th percentile is commonly used, allowing for a 5% risk of ending quarantine before symptom development. Using lower percentiles (70th or 80th) can reduce the quarantine period, but increases the risk of infected individuals being released prematurely while still being pre-symptomatic.

Assuming endemicity at the source, when solely relying on the 95th percentile of the incubation period, a quarantine of 18 days is recommended. However, using the 80th or 70th percentiles reduces the

quarantine period to 11 and 9 days, respectively. If health screening is implemented at immigration, the 95th 296 percentile of the post-entry incubation period is 15.5 days, suggesting a 2.5-day reduction in quarantine 297 period compared to using the incubation period alone. Conversely, when PCR tests (DL=250 copies/mL) are 298 299 conducted, the 95th percentile of the post-entry incubation period increases slightly, suggesting a quarantine period of 15.6 days. Even when assuming epidemic situation, we confirmed the quarantine period (i.e., the 300 95th percentile of the incubation period) is about 15.7 days with health screening and PCR tests. 301 Supplemental Figure 5 illustrates the incubation period distribution and post-entry incubation period for 302 different samples with different detection limits under epidemic and endemic situations. 303 Similar results were observed in sensitivity analyses that varied the percentile used to determine the 304 quarantine period (70th and 80th percentiles) and considered different swab types for PCR testing at 305 immigration (rectal and oropharyngeal swabs). 306

307

308 Discussion

In response to the Public Health Emergency of International Concern declared by the WHO and the identification of MPXV outside the African continent, public health authorities and other major stakeholders are evaluating the possibility of implementing immigration control measures. For example, on August 23, 2024, Singapore Ministry of Health has implemented health screenings, including temperature checks and visual assessments, at international airports and seaports for travelers and crew arriving from mpox-affected regions³⁰.

To evaluate the effectiveness of immigration control measures, we developed a mathematical model 315 to assess the proportion of infected travelers identified through health screenings and PCR testing. We found 316 that a combination of health screenings and PCR testing of saliva at immigration can identify 74% of the 317 MPXV infected travelers. Even considering more sensitive tests (i.e., 10 copies/mL as the detection limit) or 318 319 other swab sites (i.e., oropharynx and rectum samples) would not allow the identification of about 20% of MPXV infected travelers. Should public health authorities aim at fully preventing onward local transmission, 320 combining health screening and PCR testing would need to be supplemented by a quarantine period for 321 322 travelers coming from mpox-affected areas. Our findings indicate that a quarantine duration of 16 days would

be required. We also provide time-varying false negative rate estimates for various detection limits, offering

critical insights into the effectiveness of deploying different test types as they become available.

This study has some limitations. First, due to the limited clinical and epidemiological information 325 available for clade Ib, most parameters were based on clade IIb, which caused the 2022 outbreak. As more 326 relevant data becomes available for clade Ib it would be advantageous to update this modeling analysis. 327 328 Second, we did not fully account for fully asymptomatic infections in our analysis. Serological surveys and screening tests have provided evidence of asymptomatic MPXV clade IIb infections³¹⁻³³. Further research is 329 warranted to investigate the role of asymptomatic infection in MPXV transmission. Third, we only modelled 330 guarantine of individuals who may have been infected; therefore, we have not argued how to treat confirmed 331 cases such as medical treatment and isolation (to avoid further transmission). Fourth, our analysis considered 332 333 the time elapsed between exposure and arrival at the destination country. On one hand, this enables us to obtain more realistic estimation of the post-entry incubation period; on the other hand, this means that our 334 findings should be revised if the MPXV affected areas start to show larger or lower rates of local 335 transmission. Fifth, we did not consider specificity of health screening and PCR tests. In general, the 336 specificity of PCR tests is high (and considered as the gold standard test method)³⁴; however, given that 337 mpox can present with typical symptoms (such as fever), high specificity (i.e., to minimize the risk of false 338 positives) is important from an operational perspective in health screening. 339

340 It is important to stress that our study does not discuss whether or under which circumstances ITCs are 341 recommended; instead, it provides quantitative estimates of the effectiveness of a combination of health screenings and PCR tests at immigration (approximately 75% of infected travelers) and of guarantine duration 342 after arrival (approximately 2 weeks). The decision to implement public health interventions is for local 343 authorities to make based on a wider range of considerations that go beyond the effectiveness of ITCs and 344 345 quarantine, such as disease severity, likelihood of a widespread local outbreak, ability to control local spread through other measures, economic costs, strategy feasibility, among others. Furthermore, these factors may 346 evolve over time. For example, Muravama and Asakura et al.³⁵ suggested that clade Ib acquired the capacity 347 to be sexually transmitted, which is a possible explanation for the increased outbreak potential. For this reason, 348 careful thought should be taken on the right degree of surveillance at the border as the epidemiology changes. 349

References 350

- 351 1 Van Dijck, C. et al. Emergence of mpox in the post-smallpox era—a narrative review on mpox epidemiology. Clinical Microbiology and Infection 29, 1487-1492 (2023). 352 353 https://doi.org:10.1016/j.cmi.2023.08.008
- 354 2 Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLOS Neglected Tropical Diseases 16, e0010141 (2022). 355 356 https://doi.org:10.1371/journal.pntd.0010141
- 357 3 World Health Organization. Fifth Meeting of the International Health Regulations (2005) (IHR) 358 Emergency Committee on the Multi-Country Outbreak of mpox (monkeypox), <Fifth Meeting of the International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country 359 360 Outbreak of mpox (monkeypox)>(
- 361 Boisson-Walsh, A. Escalating mpox epidemic in DR Congo. The Lancet Infectious Diseases 24, 4 e487 (2024). https://doi.org:10.1016/S1473-3099(24)00446-8 362
- 5 Adebisi, Y. A., Ezema, S. M., Bolarinwa, O., Bassey, A. E. & Ogunkola, I. O. Sex Workers and the 363 Mpox Response in Africa. J Infect Dis (2024). https://doi.org:10.1093/infdis/jiae435 364
- WHO Director-General declares mpox outbreak a public health emergency of international concern, 365 6 <https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-366 public-health-emergency-of-international-concern> (367
- European Centre for Disease Prevention and Control, Communicable disease threats report, 14-20 368 7 December 2024, week 51, https://www.ecdc.europa.eu/en/publications-data/communicable-disease- 369 370 threats-report-14-20-december-2024-week-51>(
- 371 8 Grépin, K. A., Aston, J. & Burns, J. Effectiveness of international border control measures during the COVID-19 pandemic: a narrative synthesis of published systematic reviews. Philos Trans A Math 372 373 Phys Eng Sci 381, 20230134 (2023). https://doi.org:10.1098/rsta.2023.0134
- 374 Ponce, L. et al. Incubation Period and Serial Interval of Mpox in 2022 Global Outbreak Compared 9 375 with Historical Estimates. Emerg Infect Dis 30, 1173-1181 (2024). 376 https://doi.org:10.3201/eid3006.231095
- Quilty, B. J. et al. Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling 377 10 study. The Lancet Public Health 6, e175-e183 (2021). https://doi.org:10.1016/S2468-378 379 2667(20)30308-X
- 380 11 Wells, C. R. et al. Optimal COVID-19 quarantine and testing strategies. Nature communications 12, 356 (2021). https://doi.org:10.1038/s41467-020-20742-8 381
- 382 Jin, Y., Sun, T., Zheng, P. & An, J. Mass quarantine and mental health during COVID-19: A meta-12 383 analysis. Journal of Affective Disorders 295, 1335-1346 (2021). 384 https://doi.org:https://doi.org/10.1016/j.jad.2021.08.067
- 385 13 World Health Organization. COVID-19: quarantine and self-monitoring, <https://www.who.int/westernpacific/emergencies/covid-19/information/quarantine-and-self-386 monitoring>(387
- 14 Infection Control Guidance: SARS-CoV-2, <https://www.cdc.gov/covid/hcp/infection-388 389 control/index.html>(
- Lauer, S. A. et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly 390 15 Reported Confirmed Cases: Estimation and Application. Annals of internal medicine 172, 577-582 391 392 (2020). https://doi.org:10.7326/m20-0504
- Ghani, A. et al. The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. 393 16 PLoS Curr 1, Rrn1130 (2009). https://doi.org:10.1371/currents.RRN1130 394
- 395 17 Nishiura, H. & Inaba, H. Estimation of the incubation period of influenza A (H1N1-2009) among 396 imported cases: Addressing censoring using outbreak data at the origin of importation. Journal of 397 theoretical biology 272, 123-130 (2011). https://doi.org/https://doi.org/10.1016/j.jtbi.2010.12.017
- 18 Ejima, K. et al. Time variation in the probability of failing to detect a case of polymerase chain 398 399 reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. J R Soc Interface 18,
- 20200947 (2021). https://doi.org:10.1098/rsif.2020.0947 400

- Yang, Y. *et al.* Longitudinal viral shedding and antibody response characteristics of men with acute infection of monkeypox virus: a prospective cohort study. *Nature communications* 15, 4488 (2024).
 <u>https://doi.org:10.1038/s41467-024-48754-8</u>
- 404 20 Brosius, I. *et al.* Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort 405 study. *Journal of Medical Virology* **95**, e28769 (2023).
- 406 https://doi.org:https://doi.org/10.1002/jmv.28769
- 407 21 Ikeda, H. *et al.* Quantifying the effect of Vpu on the promotion of HIV-1 replication in the
- 408 humanized mouse model. *Retrovirology* **13**, 23 (2016). <u>https://doi.org:10.1186/s12977-016-0252-2</u>
- 409 22 Martyushev, A., Nakaoka, S., Sato, K., Noda, T. & Iwami, S. Modelling Ebola virus dynamics:
 410 Implications for therapy. *Antiviral Res* 135, 62-73 (2016).
- 411 <u>https://doi.org:10.1016/j.antiviral.2016.10.004</u>
- 412 23 Nowak, M. A. & May, R. M. *Virus dynamics : mathematical principles of immunology and virology.*413 (Oxford University Press, 2000).
- Jeong, Y. D. *et al.* Revisiting the guidelines for ending isolation for COVID-19 patients. *eLife* 10, e69340 (2021). <u>https://doi.org:10.7554/eLife.69340</u>
- Jeong, Y. D. *et al.* Designing isolation guidelines for COVID-19 patients with rapid antigen tests. *Nat Commun* 13, 4910 (2022). <u>https://doi.org:10.1038/s41467-022-32663-9</u>
- Allan-Blitz, L.-T. *et al.* Laboratory validation and clinical performance of a saliva-based test for
 monkeypox virus. *Journal of Medical Virology* 95, e28191 (2023).
 https://doi.org/10.1002/jmv.28191
- Nishiura, H. Determination of the appropriate quarantine period following smallpox exposure: An
 objective approach using the incubation period distribution. *International Journal of Hygiene and Environmental Health* 212, 97-104 (2009). https://doi.org/10.1016/j.jjheh.2007.10.003
- Kwok, K. O., Wei, W. I., Tang, A., Wong, S. Y. S. & Tang, J. W. Estimation of local transmissibility
 in the early phase of monkeypox epidemic in 2022. *Clin Microbiol Infect* 28, 1653.e16511653.e1653 (2022). <u>https://doi.org:10.1016/j.cmi.2022.06.025</u>
- Suñer, C. *et al.* Viral dynamics in patients with monkeypox infection: a prospective cohort study in
 Spain. *The Lancet. Infectious diseases* 23, 445-453 (2023). <u>https://doi.org:10.1016/s1473-</u>
 3099(22)00794-0
- 430 30 Ministry of Helath, Singapore, Update On Public Health Preparedness Measures for Mpox Clade I,
 431 ">https://www.moh.gov.sg/news-highlights/details/update-on-public-health-preparedness-measures-for-mpox-clade-i> (
- 433 31 De Baetselier, I. *et al.* Retrospective detection of asymptomatic monkeypox virus infections among
 434 male sexual health clinic attendees in Belgium. *Nature medicine* 28, 2288-2292 (2022).
 435 https://doi.org:10.1038/s41591-022-02004-w
- 436 32 Agustí, C. *et al.* Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or
 437 with unrecognized Mpox, in Spain. *Nature communications* 14, 5998 (2023).
 438 https://doi.org:10.1038/s41467-023-40490-9
- 439 33 Ferré, V. M. *et al.* Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men
 440 Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France.
 441 *Annals of internal medicine* 175, 1491-1492 (2022). <u>https://doi.org:10.7326/m22-2183</u>
- Sabat, J. *et al.* A comparison of SARS-CoV-2 rapid antigen testing with realtime RT-PCR among symptomatic and asymptomatic individuals. *BMC Infect Dis* 23, 87 (2023).
 https://doi.org:10.1186/s12879-022-07969-0
- Murayama, H. *et al.* Roles of community and sexual contacts as drivers of clade I mpox outbreaks.
 medRxiv, 2024.2010.2015.24315554 (2024). <u>https://doi.org:10.1101/2024.10.15.24315554</u>
- 447

448 **Data availability**

The data that support the findings of this study are available from the corresponding authors on request.

451 Code availability

- All analyses were performed with the statistical computing software R (version 4.3.3) (https://www.r-452 project.org/). The analysis using nonlinear mixed-effects modeling was performed on Monolix 2023R1 453 (https://www.lixoft.com/). study's supporting codes found 454 The can be on Github at https://github.com/SherryYuqianWang/Mpox. 455
- 456

457 Acknowledgments

- This study was supported in part by the Ministry of Education, Singapore, under its Academic Research
- 459 Fund Tier 1 Seed Award (RLMOE100201900000001), a Lee Kong Chian School of Medicine startup grant
- 460 (LKCMedicine-SUG, #022487-00001), and JST, PRESTO (JPMJPR23R3) (to KE). AE is supported by
- Japan Society for the Promotion of Science (JP22K17329) and JST (JPMJPR22R3).
- 462

463 Author contributions


- 464 Conceived and designed the study: KE, MA. Obtained and analyzed the data: KE, YW, YY, HP. Wrote the
- 465 paper: KE, YW, AE, HM, YSG, ARC, YDJ, SI, HP, BSLD, SJ, JTL, CEZC, PYC, BEY, YY, MC, DCL,
- and MA. All authors read and approved the final manuscript.
- 467

468 **Competing interest statement**

All authors declare that they have no competing interests.

Figures 470


Figure 1: Estimated viral load over time. 471



- The thick lines are the estimated mean viral load trajectories for the three sites: rectum, saliva, and 473
- 474 oropharynx. The shaded regions correspond to 50% and 95% CIs. The red horizontal line corresponds to the
- detection limit in the original study¹⁹ (10^3 copies/mL). 475
- 476

472

478 Figure 2: False-negative rates of PCR tests on rectum, saliva, and oropharynx




480 The false-negative rates of PCR tests were computed for rectum, saliva, and oropharynx over time. The

different types of lines correspond to different detection limits (10, 250, 1000 copies/mL). 481

482

Figure 3: Effectiveness of health screening and PCR tests on identifying infected travelers under 483

484 endemic situation.




485

Among travelers infected in mpox-affected countries, a portion is detected through screenings based on 486 symptom presence (dark blue) and PCR tests (light blue) conducted at immigration. We considered four 487 scenarios: health screening only (HS), health screening combined with PCR testing at a detection limit of 10 488 copies/mL (HS+PCR1), 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3). For PCR testing, we 489 simulated the use of rectum, saliva, or oropharyngeal sample assuming endemic situation. 490

492 Figure 4: Quarantine period under health screening and PCR tests at immigration assuming endemic

493 situation.



494

Quarantine period was computed as 70th, 80th, and 95th percentiles of (post-entry) incubation period 495

496 distribution. We considered four scenarios: no health screening and PCR tests (No tests), health screening

only (HS), health screening combined with PCR testing at a detection limit of 10 copies/mL (HS+PCR1), 497

250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3) under endemic situation. For PCR testing, we 498


499 simulated the use of rectum, saliva, or oropharyngeal sample assuming endemic situation.

500

Supplemental Figures 502


503 Supplemental Figure 1: Estimated viral load curve for each infected individual

- 504 The thick lines are the viral load trajectory drawn based on the best-fit parameter set for the three sites:
- 505 rectum (orange), saliva (purple), and oropharynx (pink) for individuals with detectable viral load. The
- circles correspond to observed viral load. The viral load below the detection limit (10³ copies/mL) is shown 506
- 507 by open circles.




508

Supplemental Figure 2: Rank correlation between individual parameter of the three sites



Supplemental Figure 3: Effectiveness of health screening and PCR tests on identifying infected travelers 514

515 under epidemic situation




516

Among travelers infected in mpox-affected countries, a portion is detected through screenings based on 517 symptom presence (dark blue) and PCR tests (light blue) conducted at immigration. We considered four 518 519 scenarios: health screening only (HS), health screening combined with PCR testing at a detection limit of 10 copies/mL (HS+PCR1), 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3). For PCR testing, we 520 simulated the use of rectum, saliva, or oropharyngeal sample under epidemic situation. 521

522

Supplemental Figure 4: Quarantine period under health screening and PCR tests at immigration 523 assuming epidemic situation. 524




Quarantine period was computed as 70th, 80th, and 95th percentiles of (post-entry) incubation period 526 527 distribution. We considered four scenarios: no health screening and PCR tests (No tests), health screening

- only (HS), health screening combined with PCR testing at a detection limit of 10 copies/mL (HS+PCR1), 528
- 529 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3) under epidemic situation. For PCR testing, we
- simulated the use of rectum, saliva, or oropharyngeal sample assuming epidemic situation. 530
- 531

Supplemental Figure 5: Post-entry incubation period distributions 532

- 533 The incubation period distribution and the post-entry incubation distributions. We assumed PCR tests with
- different detection limits are performed at immigration (10, 250, and 1000 copies/mL). We performed the 534
- same simulation assuming PCR tests are performed on rectum, saliva, or oropharyngeal sample assuming 535
- 536 epidemic and endemic situation.



- 538
- 539

Supplemental Tables 540

Supplemental Table 1. Variables related to infected individuals

Variables	Description		
$j(\tau)$	The number of infected travelers who reach countries without mpox outbreaks at infection age, τ		
$j_{pre}(\tau)$	Among $j(\tau)$, the number of infected travelers who are not symptomatic (pre-symptomatic)		
$j_{pre,neg}(\tau)$	Among $j(\tau)$, the number of individuals who are test negative by PCR tests performed at immigration		
i(s)	The number of infected travelers who develop symptom at time s		
$p(\tau)$	False-negative rate of PCR tests		

541

Supplemental Table 2. Epidemiological parameters for mpox

Parameter	Description	Value	Ref
$L(\tau)$	The proportion of infected travelers still presymptomatic (incubating) at infection age τ : $1 - \int_0^{\tau} f(s) ds$	Estimated from $f(\tau)$	-
$f(\tau)$	The probability density function of incubation period	lognorm(1.92,0.60) (mean=8.1, 95%ile=18)	9
R_0	Basic reproduction number	1.5	28
T_g	Mean generation time	8.7	9
r	Epidemic growth rate: $(R_0 - 1)/T_g$	Estimated from R_0 and T_g	-
k	The maximum duration of travel (days)	21	assu mpti on

542

Supplemental Table 3. Estimated model parameters for the viral dynamics model

Parameter ^a	Maximum rate constant for viral replication	Rate constant for virus infection	Death rate of infected cells	Viral load at symptom onset
Symbol	γ	β	δ	V(0)
Unit	day-1	(copies/mL) ⁻¹ day ⁻¹	day-1	copies/mL
Rectum		2.71×10 ⁻⁸ (2.44×10 ⁻⁸)	0.88 (0.27)	1.08×10^4 (9.61×10 ⁶)
Saliva	3.19 (0.66)	2.0×10 ⁻⁷ (2.4×10 ⁻⁶)	0.85 (0.25)	1.37×10^2 (3.26×10 ⁸)
Oropharynx		2.15×10 ⁻⁶ (6.3×10 ⁻⁶)	0.89 (0.25)	4.71×10^{1} (1.3×10 ⁵)

Standard deviation of the residual error^b

1.4 (0.09)

^anumbers in parentheses are the standard deviation

^bnormal distributions were assumed with mean 0

543

Supplemental Table 4. Mean, median, variance of post-entry incubation period distributions (days)					
	Mean	Median	Variance		
HS	5.8	4.5	23.6		
HS+PCR1	6.0	4.8	23.5		
HS+PCR2	6.0	4.8	23.5		
HS+PCR3	6.0	4.7	23.5		

Health screening only: HR, Health screening combined with PCR testing at a detection limit of 10 copies/mL: HS+PCR1, 250 copies/mL: HS+PCR2, 1000 copies/mL: HS+PCR3.